Analysis of Revenues
Revenues as Reported
Regeneron Pharmaceuticals Inc., income statement, revenues
US$ in thousands
| 12 months ended: | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 14,342,900) | 14,202,000) | 13,117,200) | 12,172,900) | 16,071,700) |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
Revenues exhibited a fluctuating pattern over the five-year period. Initial observation reveals a decrease followed by a period of recovery and stabilization.
- Overall Trend
- Revenues decreased significantly from 2021 to 2022, followed by a recovery phase spanning 2022 to 2025. While revenues increased from 2022 through 2025, the rate of growth slowed considerably in the latter years.
- Year-over-Year Changes
- A substantial decline in revenues occurred between 2021 and 2022, with a decrease of approximately 24.2%. Revenues then increased by 7.7% from 2022 to 2023. Further growth was observed from 2023 to 2024, representing a 9.1% increase. The increase from 2024 to 2025 was marginal, at 0.9%.
- Growth Rate Deceleration
- The rate of revenue growth decelerated markedly between 2023 and 2025. The comparatively small increase from 2024 to 2025 suggests a potential stabilization of revenue generation or a slowing of underlying growth drivers.
- Peak and Subsequent Performance
- 2021 represents the peak revenue year within the observed period. While revenues recovered following the 2022 dip, they did not surpass the 2021 level in subsequent years. The company’s revenue in 2025 remained approximately 10.7% below the 2021 peak.
In summary, the revenue stream experienced a period of disruption followed by recovery, ultimately reaching a plateau in the most recent year analyzed. Further investigation may be warranted to understand the factors contributing to the deceleration in growth and the inability to regain prior peak revenue levels.